Watertown, MA, United States of America

Bruce C Follows

This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Kymera Therapeutics, Inc.. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bruce C. Follows: Innovator in IRAK Degraders

Introduction

Bruce C. Follows is an accomplished inventor based in Watertown, MA (US). He has made significant contributions to the field of biochemistry, particularly through his innovative work on IRAK degraders. His expertise and dedication to research have led to the development of valuable compounds and methods that have potential applications in therapeutic settings.

Latest Patents

Bruce holds a patent for "IRAK degraders and uses thereof." This invention provides compounds, compositions, and methods for utilizing these degraders, showcasing his commitment to advancing scientific knowledge and practical applications in medicine.

Career Highlights

Currently, Bruce is associated with Kymera Therapeutics, Inc., where he continues to push the boundaries of innovation in drug development. His work at Kymera Therapeutics focuses on harnessing the power of targeted protein degradation to create novel therapies for various diseases.

Collaborations

Throughout his career, Bruce has collaborated with notable colleagues, including Nello Mainolfi and Chris De Savi. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

In summary, Bruce C. Follows is a prominent inventor whose work on IRAK degraders has the potential to impact therapeutic strategies significantly. His contributions to the field of biochemistry exemplify the spirit of innovation and collaboration in scientific research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…